Onconews

Upregulation do HER2 após terapia endócrina neoadjuvante no câncer de mama HR+/HER2-negativo e sobrevida em 5 Anos no estudo WSG-ADAPT-TP

Listen Later

Referências: 

  1. Chaudhary
    2. LN, Jorns J, Sun Y, Cheng YC, Kamaraju S, Burfeind J, Gonyo M, Kong A, Patten
    C, Yen T, Cortina C, Carson E, Johnson N, Bergom C, Tsaih SW, Banerjee A, Wang
    Y, Chervoneva I, Weil E, Chitambar CR, Rui H. Frequent Upregulation Of HER2
    Protein In Hormone Receptor-Positive HER2-Negative Breast Cancer After
    Short-Term Neoadjuvant Endocrine Therapy. Res Sq [Preprint]. 2023 Apr
    7:rs.3.rs-2777910. doi: 10.21203/rs.3.rs-2777910/v1. Update in: Breast Cancer
    Res Treat. 2023 Jul 17;: PMID: 37066270; PMCID: PMC10104267. https://www.researchsquare.com/article/rs-2777910/v1
  2. Harbeck
    3. N, Nitz UA, Christgen M, Kümmel S, Braun M, Schumacher C, Potenberg J, Tio J,
    Aktas B, Forstbauer H, Grischke EM, Scheffen I, Malter W, von Schumann R, Just
    M, Zu Eulenburg C, Biehl C, Kolberg-Liedtke C, Deurloo R, de Haas S, Jóźwiak K,
    Hauptmann M, Kates R, Graeser M, Wuerstlein R, Kreipe HH, Gluz O; WSG-ADAPT
    investigators. De-Escalated Neoadjuvant Trastuzumab-Emtansine With or Without
    Endocrine Therapy Versus Trastuzumab With Endocrine Therapy in HR+/HER2+ Early
    Breast Cancer: 5-Year Survival in the WSG-ADAPT-TP Trial. J Clin Oncol. 2023
    Aug 1;41(22):3796-3804. doi: 10.1200/JCO.22.01816. Epub 2023 Feb 21. PMID:
    36809046. https://ascopubs.org/doi/10.1200/JCO.22.01816

     

    --

    ...more
    View all episodesView all episodes
    Download on the App Store
    OnconewsBy onconews